news
Compass Pathways plans FDA submission for COMP360 psilocybin within two weeks
Compass Pathways confirmed it will file its New Drug Application for COMP360 psilocybin with the FDA within two weeks. The formulation targets treatment-resistant depression in patients who failed at least two previous antidepressants. If accepted, it puts the first commercial psilocybin protocol directly before US regulators.
Compass Pathways confirmed it will file its New Drug Application for COMP360 psilocybin with the FDA within two weeks. The formulation targets treatment-resistant depression in patients who failed at least two previous antidepressants. If accepted, it puts the first commercial psilocybin protocol directly before US regulators.
The architecture take
The psychedelic sector held its breath after the FDA threw out Lykos's MDMA application in August, but Compass is betting a pure synthetic molecule and standardized psychological support can survive where therapy-heavy protocols stumbled. I used to think the FDA would stall psychedelic approvals for another five years after that advisory committee meltdown. I was wrong about their timeline. COMP360 works primarily at the 5-HT2A serotonin receptor, essentially breaking rigid default mode network connectivity to allow depressive brains temporary plasticity. What Compass wants is clean medicalization: a single 25mg dose administered in a clinical room with two trained therapists, billed through traditional insurance codes. I watched their Phase 2 data closely, and the drop in depression scores was swift, though the durability at week 12 started tapering for about half the cohort. If the agency accepts the filing, the debate moves from whether psilocybin works on stubborn neurochemistry to who actually pays for the six hours of therapist supervision in the room.